PMVP
PMV Pharmaceuticals, Inc.Healthcare·Biotechnology
$1.20
$64M market cap
Revenue
$0.0M
Free Cash Flow
$-36.9M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was for
2-Year Price History
$1.26-24.1%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -19.0 | -19.0 | -18.0 | -19.7 | -19.7 | -0.0 | 93.6 | 0.3 | 53.3 | -446.2% | -- | -- |
| Act | 2025-Q4 | 0.0 | -19.2 | -19.2 | -18.0 | -17.2 | -17.2 | -0.0 | 112.9 | 0.8 | 53.3 | -220.8% | -- | -- |
Valuation & Metrics
Market Stats
Price$1.20
Market Cap$64M
Enterprise Value$-29M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-57.6%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-36.1M
Free Cash Flow$-36.9M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-333.5%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares2.6M
Days to Cover7.6
Change (vs Prior)+13.8%
Need at least 2 settlement dates for chart
Employees
Headcount47
Revenue / Employee$0
Gross Profit / Employee$-723
Cash Runway
30.4months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
60.4%(+6.8% YoY)
57 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
7.3%(+0.6% YoY)
7 filers
Vanguard, iShares, SPDR
Market makers
0.3%(+0.3% YoY)
5 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| BML Capital Management, LLC | $6.6M | $1.42 | +$35K | +$1.9M | -1.2% | $155M |
| TANG CAPITAL MANAGEMENT LLC | $5.3M | $1.40 | −$862K | +$5.3M | -5.6% | $1.93B |
| Sio Capital Management, LLC | $3.8M | $1.53 | +$546K | −$817K | -1.2% | $694M |
| ArrowMark Colorado Holdings LLC | $3.6M | $3.48 | −$269K | −$541K | -4.3% | $3.74B |
| Euclidean Capital LLC | $3.3M | $6.23 | +$0 | +$0 | -3.7% | $392M |
| Eversept Partners, LP | $2.9M | $1.24 | +$2.9M | +$2.9M | -0.3% | $1.52B |
| ACADIAN ASSET MANAGEMENT LLC | $2.7M | $2.12 | +$248K | +$209K | -0.5% | $70.48B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $2.4M | $1.24 | +$2.4M | +$2.4M | — | $4.04T |
| TWO SIGMA INVESTMENTS, LP | $2.3M | $1.68 | +$1.5M | +$1.9M | -0.9% | $117.03B |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $2.3M | $1.24 | +$2.2M | +$2.3M | — | $64.61B |
| BlackRock, Inc.Passive | $1.1M | $1.49 | −$273K | −$335K | -0.2% | $5.69T |
| MORGAN STANLEY | $1.1M | $1.55 | +$949K | +$1.0M | -0.3% | $1.65T |
| Stonepine Capital Management, LLC | $878K | $1.37 | −$549K | +$97K | -5.9% | $113M |
| Longaeva Partners L.P. | $685K | $1.24 | +$685K | +$685K | -0.5% | $2.08B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $615K | $7.33 | +$62K | +$81K | +2.3% | $1.61T |
| Aldebaran Capital, LLC | $587K | $1.56 | −$6K | −$62K | -1.4% | $131M |
| MARSHALL WACE, LLP | $538K | $2.20 | −$38K | +$538K | +0.6% | $92.71B |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $532K | $2.46 | +$0 | +$347K | -2.3% | $4.93B |
| Assenagon Asset Management S.A. | $447K | $1.34 | +$273K | +$305K | +0.1% | $62.57B |
| Walleye Capital LLC | $416K | $2.00 | +$0 | +$290K | -14.9% | $15.09B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
-2.17%
avg per quarter
Holders (ex-self)
-2.13%
excl. this stock
Buyers (this Q)
-0.18%
24 buyers · $0.01B in
Sellers (this Q)
-3.45%
25 sellers · $0.00B out
alpha coverage: 94% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+2.6%
how holders react when this stock falls
On quiet Qs
+0.4%
−10% to +10% baseline
On rallies (+10%+)
-27.2%
how they react when this stock rises
Holders' portfolio flow this Q
+8.5%
inflows — adds are organic
Sellers' portfolio flow this Q
+0.2%
Sellers' overall flow ~ flat.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-1.7%
Holder mid (any stock)
-4.4%
Holder rally (any stock)
-8.9%
Biggest decreases this quarter
ORBIMED ADVISORS LLCexited−$6.2MTANG CAPITAL MANAGEMENT LLC−$862Kα-5.6Stonepine Capital Management, LLC−$549Kα-5.9BlackRock, Inc.−$273Kα-0.2ArrowMark Colorado Holdings LLC−$269Kα-4.3XTX Topco Ltdexited−$131KSUSQUEHANNA INTERNATIONAL GROUP, LLPexited−$98KMARSHALL WACE, LLP−$38Kα+0.6TWO SIGMA SECURITIES, LLCexited−$29KBAILARD, INC.exited−$21K
New buyers this quarter
Top-5 holders · 49.1%
BML Capital Management, LLC--
TANG CAPITAL MANAGEMENT LLC--
Sio Capital Management, LLC--
ArrowMark Colorado Holdings LLC--
Euclidean Capital LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
ORBIMED ADVISORS LLC—INTERWEST VENTURE MANAGEMENT CO—Euclidean Capital LLC2.6MMORGAN STANLEY864KAvoro Capital Advisors LLC—RTW INVESTMENTS, LP—Boxer Capital, LLC—JPMORGAN CHASE & CO214VIKING GLOBAL INVESTORS LP—RA CAPITAL MANAGEMENT, L.P.—
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$5.0031670.0%
Last Year (1 analysts)$5.0031670.0%
Current Price$1.20
Analyst Ratings
4
Buy: 4Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$152K
4 txns · 4 insiders · 142,876 sh
Major holders (≥10% beneficial owners)
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$2.42M
2 txns · 1 insider · 1,500,000 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2025-10-23 | SELL | ORBIMED ADVISORS LLC | 10 percent owner | 1,000,000 | $1.52 | $1.52M | $7.56M |
| 2025-09-10 | SELL | ORBIMED ADVISORS LLC | 10 percent owner | 500,000 | $1.80 | $900K | $10.76M |
| 2025-07-01 | SELL | Carulli Michael | officer: Chief Financial Officer | 28,249 | $1.06 | $30K | $64K |
| 2025-07-01 | SELL | Jalota Deepika | officer: Chief Development Officer | 33,065 | $1.06 | $35K | $96K |
| 2025-07-01 | SELL | Mack David Henry | director, officer: President and CEO | 58,411 | $1.06 | $62K | $571K |
| 2025-07-01 | SELL | Ticktin Robert | officer: General Counsel & COO | 23,151 | $1.06 | $25K | $105K |
Order Flow (FINRA, ~3w lag)
33.7%retail-2.7pp
26.9%dark+5.2pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
PMV Pharmaceuticals: Clinical Burn Meets Aggressive Option Repricing
Overall Risk
7/10
Fraud
2/10
Dilution
8/10
Insolvency
6/10
Earnings Overstated
3/10
Hidden Liabilities
2/10
Legal
2/10
Audit Warnings
4/10
Hidden Upside
2/10
Contextually Acceptable
7/10